BACKGROUND: In certain parts of Africa, type-specific herpes simplex virus type 2 (HSV-2) ELISAs may have limited specificity. To date, no study has been conducted to validate HerpeSelect and Kalon type-specific HSV-2 ELISAs using both the Western blot and recombinant gG ELISA inhibition testing as reference standards. METHODS: A total of 120 men who were HIV seronegative (aged 18-24 years) provided blood samples. HSV-2 IgG serum antibodies were detected using four different methods: HerpeSelect HSV-2 ELISA (n = 120), Kalon HSV-2 ELISA (n = 120), University of Washington Western blot (n = 101) and a recombinant inhibition test (n = 93). RESULTS: HSV-2 seroprevalence differed significantly by HSV-2 detection method, ranging from 24.8% with the Western blot to 69.8% with the HerpeSelect ELISA. Using the Western blot as the reference standard, the HerpesSelect had the highest sensitivity for HSV-2 antibody detection (100%) yet lowest specificity (40%). Similar results were obtained using the inhibition test as the reference standard. The sensitivity and specificity of the Kalon test versus the Western blot were 92% and 79%, respectively, and 80% and 82% versus the inhibition test. Using the inhibition test as the reference standard, the sensitivity of the Western blot appeared low (49%). CONCLUSIONS: In men in western Kenya who were HIV seronegative, the HerpeSelect and Kalon type-specific ELISAs had high sensitivities yet limited specificities using the Western blot as reference standard. Overall, the Kalon ELISA performed better than the HerpeSelect ELISA in these young men from Kisumu. Further understanding is needed for the interpretation of HSV-2 inhibition or ELISA test positive/ Western blot seronegative results. Before HSV-2 seropositivity may be reliably reported in selected areas of Africa, performance studies of HSV-2 serological assays in individual geographical areas are recommended.
BACKGROUND: In certain parts of Africa, type-specific herpes simplex virus type 2 (HSV-2) ELISAs may have limited specificity. To date, no study has been conducted to validate HerpeSelect and Kalon type-specific HSV-2 ELISAs using both the Western blot and recombinant gG ELISA inhibition testing as reference standards. METHODS: A total of 120 men who were HIV seronegative (aged 18-24 years) provided blood samples. HSV-2 IgG serum antibodies were detected using four different methods: HerpeSelect HSV-2 ELISA (n = 120), Kalon HSV-2 ELISA (n = 120), University of Washington Western blot (n = 101) and a recombinant inhibition test (n = 93). RESULTS:HSV-2 seroprevalence differed significantly by HSV-2 detection method, ranging from 24.8% with the Western blot to 69.8% with the HerpeSelect ELISA. Using the Western blot as the reference standard, the HerpesSelect had the highest sensitivity for HSV-2 antibody detection (100%) yet lowest specificity (40%). Similar results were obtained using the inhibition test as the reference standard. The sensitivity and specificity of the Kalon test versus the Western blot were 92% and 79%, respectively, and 80% and 82% versus the inhibition test. Using the inhibition test as the reference standard, the sensitivity of the Western blot appeared low (49%). CONCLUSIONS: In men in western Kenya who were HIV seronegative, the HerpeSelect and Kalon type-specific ELISAs had high sensitivities yet limited specificities using the Western blot as reference standard. Overall, the Kalon ELISA performed better than the HerpeSelect ELISA in these young men from Kisumu. Further understanding is needed for the interpretation of HSV-2 inhibition or ELISA test positive/ Western blot seronegative results. Before HSV-2 seropositivity may be reliably reported in selected areas of Africa, performance studies of HSV-2 serological assays in individual geographical areas are recommended.
Authors: Robert C Bailey; Stephen Moses; Corette B Parker; Kawango Agot; Ian Maclean; John N Krieger; Carolyn F M Williams; Richard T Campbell; Jeckoniah O Ndinya-Achola Journal: Lancet Date: 2007-02-24 Impact factor: 79.321
Authors: Oliver Laeyendecker; Charla Henson; Ronald H Gray; Ruby H-N Nguyen; Bobbi Jo Horne; Maria J Wawer; David Serwadda; Noah Kiwanuka; Rhoda Ashley Morrow; Wayne Hogrefe; Thomas C Quinn Journal: J Clin Microbiol Date: 2004-04 Impact factor: 5.948
Authors: Eddy van Dyck; Anne Buvé; Helen A Weiss; Judith R Glynn; David W G Brown; Bénédicte De Deken; John Parry; Richard J Hayes Journal: J Clin Microbiol Date: 2004-07 Impact factor: 5.948
Authors: Dennis A Benson; Ilene Karsch-Mizrachi; David J Lipman; James Ostell; David L Wheeler Journal: Nucleic Acids Res Date: 2007-01 Impact factor: 16.971
Authors: J Lingappa; E Nakku-Joloba; A Magaret; D Friedrich; J Dragavon; F Kambugu; M Joloba; C Whalen; R Coombs; C Celum; R Ashley Morrow Journal: Int J STD AIDS Date: 2010-09 Impact factor: 1.359
Authors: Musa Otieno Ng'ayo; David Friedrich; King K Holmes; Elizabeth Bukusi; Rhoda Ashley Morrow Journal: J Virol Methods Date: 2009-10-23 Impact factor: 2.014
Authors: Supriya D Mehta; Stephen Moses; Corette B Parker; Kawango Agot; Ian Maclean; Robert C Bailey Journal: AIDS Date: 2012-06-01 Impact factor: 4.177
Authors: Denise Dion Hallfors; Hyunsan Cho; Isabella I Mbai; Benson W Millimo; Carolyne Atieno; David Okumu; Winnie K Luseno; Shane Hartman; Carolyn T Halpern; Marcia M Hobbs Journal: Sex Transm Infect Date: 2015-07-02 Impact factor: 3.519
Authors: Haile Selassie Okuku; Eduard J Sanders; Joyce Nyiro; Caroline Ngetsa; Eric Ohuma; R Scott McClelland; Matthew A Price; Susan M Graham Journal: Sex Transm Dis Date: 2011-09 Impact factor: 2.830
Authors: Susanna L Lamers; Ruchi M Newman; Oliver Laeyendecker; Aaron A R Tobian; Robert C Colgrove; Stuart C Ray; David M Koelle; Jeffrey Cohen; David M Knipe; Thomas C Quinn Journal: J Virol Date: 2015-05-27 Impact factor: 5.103
Authors: Aaron A R Tobian; Godfrey Kigozi; Maria J Wawer; David Serwadda; Thomas C Quinn; Ronald H Gray Journal: AIDS Date: 2013-01-02 Impact factor: 4.177
Authors: Anthony N Muiru; Brandon L Guthrie; Rose Bosire; Michele Merkel; Amy Y Liu; Robert Y Choi; Barbara Lohman-Payne; Ann Gatuguta; Romel D Mackelprang; James N Kiarie; Carey Farquhar Journal: J Infect Dis Date: 2013-07-09 Impact factor: 5.226